Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Here's everything we know so far about the latest terrorist incident in France.
A minimum number of black players will have to be selected in all national teams, with the target calculated on an annual basis.
Western areas will see the rain first but by the end of the day it will also have spread eastwards.